Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Maria Celentano"'
Autor:
Flavia Antonucci, Serena Marotta, Maria Celentano, Mariangela Pedata, Cira Riccardi, Cristina Luise, Angela Carobene, Simona Maria Muggianu, Assunta Viola, Mafalda Caputo, Stefania Leone, Ilaria Migliaccio, Barbara Pocali, Mirella Alberti, Claudio Falco, Mario Toriello, Felicetto Ferrara, Alessandra Picardi
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
To date, the effect of blinatumomab and donor lymphocyte infusion association as a salvage treatment for acute lymphoblastic leukemia (ALL) relapse after allogeneic transplant procedure is still unknown. Here, we report a case report of a patient wit
Externí odkaz:
https://doaj.org/article/696d4a34f3cc49e0827dfbf48df98890
Autor:
Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier
Publikováno v:
Clinical Management Issues, Vol 6, Iss 2S, Pp 11-14 (2015)
Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological r
Externí odkaz:
https://doaj.org/article/52a2341672a54f938c2de15a524c96e6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Ciências jurídicas: Certezas, dilemas e perspectivas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fdeb61f016dea85ac5e59e87927f9d6
https://doi.org/10.22533/at.ed.7272122117
https://doi.org/10.22533/at.ed.7272122117
Autor:
Irene Terrenato, Giulia Regazzo, Cira Riccardi, Silvia Maria Trisolini, Saveria Capria, Felicetto Ferrara, Laura Ballotta, Maria Celentano, Costantino Riemma, Francesco Marchesi, Andrea Mengarelli, Mariangela Pedata, Alessandra Picardi, Elena Papa
Publikováno v:
Leukemialymphoma. 61(9)
BEAM conditioning regimen (Carmustine, Etoposide, Cytarabine and Melphalan) is the currently standard for lymphoma patients undergoing an autologous hematopoietic stem cell transplant (ASCT) [1–2]....
Autor:
Rossella Fabbricini, Ursula Sessa, Vincenzo Mettivier, Olimpia Finizio, Stefano Rocco, Maria Celentano
Publikováno v:
Clinical Management Issues, Vol 6, Iss 2S, Pp 11-14 (2015)
Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological r
Autor:
Maria Celentano, Salvatore Guastafierro, Raffaele Rossiello, Amando Tedeschi, Clelia Criscuolo, Umberto Falcone, Luigi Cobellis
Publikováno v:
Acta Haematologica. 128:33-38
Primary lymphoma of the female genital tract is very rare. We report the case of a 36-year-old woman who was referred to our hospital because of an indeterminate Pap smear test. The colposcopy showed a thickening of the posterior vaginal wall and var
Autor:
Felicetto Ferrara, Tiziana Izzo, Maria Celentano, Giuseppina Mele, Cira Riccardi, Clelia Criscuolo
Publikováno v:
American Journal of Hematology. 85:687-690
The strategy named double induction (DI) in acute myeloid leukemia (AML) consists of two courses of chemotherapy irrespective of the degree of cytoreduction in the bone marrow (BM) after the first course, unless severe complications prohibit its appl
Autor:
Maria Rosaria D'Amico, Filiberto Pollio, Carolina Copia, Ettore Mariano Schiavone, Salvatore Palmieri, Assunta Viola, Maria Celentano, Felicetto Ferrara
Publikováno v:
Hematological Oncology. 24:73-77
Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (n = 23) or in refractory relapse (RR) (n = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). Salvage treatm
Autor:
Antonello Sica, Salvatore Guastafierro, Milena Coppola, Maria Giovanna Ferrara, Umberto Falcone, Maria Celentano
Publikováno v:
Leukemia Research. 33:1079-1081
Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is kn